NAPSRx

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s CYRAMZA® (ramucirumab) combined with paclitaxel (a type of chemotherapy) to treat individuals with a progressive form of  metastatic gastric (stomach) or gastroesophageal...

Astellas will collaborate with Proteostasis Therapeutics, Inc to develop novel therapeutic contenders that modulate Unfolded Protein Response (UPR) utilizing Proteostasis’ proprietary “Disease Relevant Translation” (DRT™) and “Proteostasis...

According to a new study published in the journal Neuropharmacology conducted by research academics at Lancaster University, certain type 2 diabetes drugs on the market have produced neuroprotective effects in a mouse model of Alzheimer's disease.

Abbvie has disclosed their Q3 report for 2014 and once again their breakthrough therapeutic treatment HUMIRA is leading the way in sales. Worldwide sales of HUMIRA increased 17.5 percent raking in $3.26 billion.

Abilify is found to be the preferred brand for the treatment of Schizophrenia according to surveyed U.S. Psychiatrists and Payers

The Bayer Group has released their third quarter earnings for the 2014 financial year and the company beat analysts’ expectations posting a 13% rise in third-quarter net profit.

Bristol-Myers Squibb (BMS) has announced their plans to enter into an agreement with F-star Alpha Ltd. giving them the option to obtain the worldwide rights to FS102, a novel Phase 1 ready Human Epidermal growth factor Receptor 2 (HER2)-targeted therapy.

In a strategic move to strengthen their vaccine division, Australia’s CSL Ltd will pay Novartis $275 million for their global influenza vaccine business.

“The approval of this product provides an important therapeutic option for use in the care of patients with this rare disease,” said Karen Midthun, MD, director of FDA’s Center for Biologics Evaluation and Research.

Celgene Corporation had a remarkable financial third quarter earning a net income of $508 million for 2014 compared to $372 million in 2013.